(Q38238600)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109953%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

title

Resistance acquisition to MDM2 inhibitors (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109953%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

author name string

Daniel Speidel

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109953%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

Ian Hardcastle

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109953%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

publication date

1 August 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109953%20AND%20SRC:MED&resulttype=core&format=json

Biochemical Society Transactions

12 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109953%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

volume

42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109953%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109953%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

page(s)

752-757

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109953%20AND%20SRC:MED&resulttype=core&format=json

Molecular aspects of cancer cell resistance to chemotherapy

12 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Tumour heterogeneity and drug resistance: personalising cancer medicine through functional genomics

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Timeline: Chemotherapy and the war on cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Therapeutic exploitation of the p53 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

The first 30 years of p53: growing ever more complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Reactivation of p53: from peptides to small molecules.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Pharmacological inhibition of Mdm2 triggers growth arrest and promotes DNA breakage in mouse colon tumors and human colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Patented inhibitors of p53-Mdm2 interaction (2006 - 2008).

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Mdm2 and MdmX inhibitors for the treatment of cancer: a patent review (2011-present).

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

In vivo activation of the p53 pathway by small-molecule antagonists of MDM2

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Discovery of RG7388, a potent and selective p53-MDM2 inhibitor in clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Isoindolinone-based inhibitors of the MDM2-p53 protein-protein interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

1,4-Benzodiazepine-2,5-diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

The central valine concept provides an entry in a new class of non peptide inhibitors of the p53-MDM2 interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Structure-based design of novel inhibitors of the MDM2-p53 interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Diaryl- and triaryl-pyrrole derivatives: inhibitors of the MDM2-p53 and MDMX-p53 protein-protein interactions†Electronic supplementary information (ESI) available: Experimental details for compound synthesis, analytical data for all compounds and in

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Rational design and binding mode duality of MDM2-p53 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Design, synthesis and biological evaluation of novel 3,4,5-trisubstituted aminothiophenes as inhibitors of p53-MDM2 interaction. Part 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Targeting p53 by small molecules in hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

MDM2, MDMX and p53 in oncogenesis and cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Nongenotoxic p53 activation protects cells against S-phase-specific chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

p53-Based cyclotherapy: exploiting the 'guardian of the genome' to protect normal cells from cytotoxic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Recent advances in the therapeutic perspectives of Nutlin-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Molecular mimicry-based repositioning of nutlin-3 to anti-apoptotic Bcl-2 family proteins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

MDM2 antagonist nutlin-3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Initial testing of JNJ-26854165 (Serdemetan) by the pediatric preclinical testing program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Adaptation of cancer cells from different entities to the MDM2 inhibitor nutlin-3 results in the emergence of p53-mutated multi-drug-resistant cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

In vitro selection of mutant HDM2 resistant to Nutlin inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Human neuroblastoma cells with acquired resistance to the p53 activator RITA retain functional p53 and sensitivity to other p53 activating agents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Small-molecule activation of p53 blocks hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in vivo and leads to tumor cell apoptosis in normoxia and hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Protecting the genome from mdm2 and mdmx

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

Mechanisms of acquired resistance to targeted cancer therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

A Phase I First-in-Human Pharmacokinetic and Pharmacodynamic Study of Serdemetan in Patients with Advanced Solid Tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1042%2FBST20140035

21 January 2018

Identifiers

DOI

10.1042/BST20140035

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25109953%20AND%20SRC:MED&resulttype=core&format=json

12 March 2020

1 reference